Answers are grounded in this paper and cite their sources.
Treatment of anemia in Chronic Kidney Disease (CKD), a problem of public health proportions, involves utilization of invasive and costly treatment options. Moreover, recent clinical trials have revealed several complications arising from the use of erythropoiesis stimulating agents in the treatment of anemia of CKD. There is an unmet need for safer, cheaper and effective treatment options for anemia of CKD.
No takes yet. Share an insight, caveat, or question.
Bhupesh Panwar (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: